We introduce ourselves
Our cell line development timelines and innovation are unprecedented. This is our focus, which is why we do it best. Ultimately, we help companies get drugs to patients faster and more cost-effectively.
From our laboratories in Geneva, Switzerland, our primary business is developing Chinese Hamster Ovary (CHO) cell technologies that help biopharma companies around the world create therapeutic biologics. The term biologics refers to a wide range of drugs manufactured in living systems. Selexis helps its partners realize the full potential of their biotherapeutic programs, allowing them to reach patients with new treatments faster. In 2020, our partners’ clinical programs using our Selexis SUREtechnology™ Platform have grown to 136. We celebrated two marketed products from our partners, bringing us to 8 marked products in the areas of oncology and auto-immune diseases.
The Selexis SUREtechnology Platform™ improves the way mammalian cells are used in the discovery, development and manufacturing of recombinant proteins and drugs.
